Summary & Overview
CPT 0356U: NavDx® HPV Cell‑free DNA Test for Cancer Recurrence
Headline: New CPT code 0356U identifies NavDx® cell–free DNA test for HPV‑associated cancer surveillance
Lead: CPT code 0356U designates NavDx®, a proprietary laboratory assay that evaluates cell–free DNA from oropharyngeal or anal specimens for 17 human papillomavirus (HPV)–related DNA biomarkers and provides an algorithmic assessment of cancer recurrence risk. The code formalizes billing for a single-vendor molecular test increasingly used in post‑treatment surveillance.
Why it matters: Adoption of CPT code 0356U standardizes claims reporting for a targeted circulating tumor DNA test tied to HPV‑associated cancers, with implications for coverage, utilization tracking, and comparative benchmark analyses across national payers.
Payers covered: Analysis addresses national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: This publication summarizes the clinical context for CPT code 0356U, expected sites of service, and how the test is reported in claims. Readers will find an overview of payer coverage considerations, common billing practices, and the role of proprietary laboratory analyses in cancer surveillance. The report outlines available benchmarks and policy updates where applicable and highlights clinical implications for post‑treatment monitoring of HPV‑associated malignancies.
Scope: National coverage; data-driven benchmarks and payer policy summaries where available. Data not available in the input is identified explicitly.
Billing Code Overview
CPT code 0356U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to a single laboratory test: NavDx® by Naveris Inc. The test analyzes cell–free DNA from an oropharyngeal or anal specimen to detect 17 DNA biomarkers associated with human papillomavirus–associated cancer. An algorithmic result indicates the likelihood of cancer recurrence following treatment, supporting surveillance and clinical decision-making.
Service Type: Clinical laboratory molecular diagnostic testing using cell–free DNA analysis with algorithmic interpretation.
Typical Site of Service: Clinical laboratories and outpatient specimen collection sites where oropharyngeal or anal specimens are obtained and sent for proprietary laboratory analysis.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a history of oropharyngeal squamous cell carcinoma treated with definitive chemoradiation presents for routine surveillance. The treating head and neck oncologist orders NavDx® to evaluate cell-free HPV DNA from an oropharyngeal swab to assess for molecular evidence of residual disease or early recurrence. The clinical workflow: sample collection of an oropharyngeal or anal swab in the clinic, proper labeling and courier transport to the proprietary laboratory (Naveris Inc.), laboratory extraction and targeted sequencing of cell‑free DNA for 17 HPV‑related DNA biomarkers, algorithmic risk scoring for recurrence, and return of the report to the ordering clinician. Results are used as an adjunct to clinical exam, imaging, and endoscopy during post‑treatment surveillance to stratify recurrence risk and guide subsequent diagnostic imaging or biopsy decisions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician interpretation component separate from the laboratory technical component if applicable and allowed. |
TC | Technical component | Use when billing only the laboratory technical component of the test when the performing lab bills separately. |